XING Diagnostics has extensive experience in designing disruptive technologies for the accurate screening and diagnosis of infectious diseases and cancers. XING has extremely high standards of product development and proprietary bioinformatics which are supported by state-of-the-art technology, laboratory management systems, and facilities. The company has an operating pathology laboratory which is accredited by NATA under ISO15189 with RCPA endorsement. XING’s analytical capabilities are supported by the latest equipment to ensure comprehensive analysis for use in point-of-care diagnostics and cancer oncology.
In 2021, the Xing Biodefence has been selected as a 2021 TiE50 Winner in the prestigious TiE50 Awards Program. This ten year old awards competition is a program of TiEcon, the world's largest conference for tech entrepreneurs. XING Biodefense Systems was recognized for its XavTrap® recombinant platform